A quantitative neovascularization assay for screening pro- and anti-angiogenic factors
(English)Manuscript (preprint) (Other academic)
Therapeutic regulation of tissue vascularization has appeared as an attractive approach to treat a number of human diseases. However, promising results obtained in animal models have largely failed when translated into clinical trials. This suggests that current experimental models do not properly reflect the physiological situation and that there is a need for new in vivo assay that allows quantitative and qualitative analysis of non-developmental neovascularization. In this report we present a new assay where the effects of activators and inhibitors of neovascularization can be quantitatively measured. A provisional matrix composed of collagen and fibrin was formed in a plastic cylinder and implanted onto the chick chorioallantoic membrane. A nylon mesh separated the implanted matrix from the underlying tissue to distinguish new from pre-existing vessels. Vascularization of the matrix in response to FGF-2 and PDGF-BB was scored in a double-blinded manner, or vessel density measured using a semi-automated image analysis procedure. Evaluation of thalidomide, fumagillin, wortmannin, cortisol and U0126, which are compounds that has been reported to inhibit angiogenesis, revealed that while some only inhibited ingrowth of neo-vessels into the matrix, others also caused pre-existing vessels to regress. This quantitative, inexpensive and rapid in vivo angiogenesis assay might be a valuable tool in screening and characterizing factors that influence tissue vascularization.
Medical and Health Sciences
Research subject Medicine
IdentifiersURN: urn:nbn:se:uu:diva-113061OAI: oai:DiVA.org:uu-113061DiVA: diva2:289573